PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8867181

Options in asthma management.

R Adams·R Ruffin
View original source ↗Export metadata ↓

Abstract

This paper emphasises the strategies that can be used by general practitioners in the management of asthma and reviews the new medications available for the severe asthmatic population. The principles of asthma management involve the assessment of asthma severity and the assessment of risk factors. An effective review process entails: identification of immediate patient concerns; a review of symptoms; lung function; and detection of altered compliance. In the setting of poor compliance additional strategies can be applied. Three relatively new medications are available. Salmeterol (long acting beta 2 agonist) and fluticasone (inhaled corticosteroid) are for use in the small proportion of asthmatics who have severe asthma. Nedocromil sodium is a cromoglycate-like drug mainly suitable for treatment of milder asthmatics.

Explore related subjects

Administration, InhalationAdministration, OralAdrenal Cortex HormonesAirway ResistanceAnti-Asthmatic AgentsAsthmaBronchodilator AgentsDrug Therapy, CombinationHumansJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Adams, R Ruffin. 1996. Options in asthma management.. https://pubmed.ncbi.nlm.nih.gov/8867181/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗